-

Twist Bioscience to Present at Upcoming Virtual Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming virtual investor conferences:

  • SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26; fireside chat at 11:20 a.m. Eastern Time.
  • Cowen 41st Annual Healthcare Conference on Thursday, March 4; fireside chat at 1:30 p.m. Eastern Time, and Synthetic Biology CEO Panel at 2:50 p.m. Eastern Time.
  • Barclays Global Healthcare Conference on Tuesday, March 9; fireside chat at 10:20 a.m. Eastern Time.

The fireside chats will be webcast live and can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company's website here. A replay of the fireside chats will be archived for a period of 30 days following conclusion of the live events.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Contacts

Angela Bitting
SVP, Corporate Affairs
925- 202-6211
abitting@twistbioscience.com

Twist Bioscience Corporation

NASDAQ:TWST

Release Versions
Hashtags

Contacts

Angela Bitting
SVP, Corporate Affairs
925- 202-6211
abitting@twistbioscience.com

Social Media Profiles
More News From Twist Bioscience Corporation

Twist Bioscience to Report Fiscal 2021 Second Quarter Financial Results on Thursday, May 6, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2021 second quarter ended March 31, 2021, following the close of market on Thursday, May 6, 2021. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time...

Twist Bioscience to Expand Oregon Lease, Supporting Future Growth

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has exercised its right of first refusal to expand the lease for its “Factory of the Future” manufacturing facility near Portland, Oregon. The expanded lease secures an additional approximately 100,000-square-foot facility within the same building as the approximat...

Pure Biologics Selects Twist Bioscience to Expand Phage Display Technology Capabilities

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a partnership with Pure Biologics to accelerate the discovery of immuno-oncology antibody-based drugs. “Twist’s unique technological approaches and abilities allow for the rapid generation of diverse synthetic libraries with novel and recent data-based randomization scheme...
Back to Newsroom